Citations

Clear

1055 citation(s) found for "Small, J C".

Comparing impact of treatment before or after surgery in patients with stage II-IIIb resectable non-small cell lung cancer (NSCLC; Alliance A082304-SWOG S2402).
Aljumaily, Raid, Mandrekar, Sumithra J. , Zhao, Ying‐Qi , Martin, Linda W. , Hillman, Shauna L., Chiang, Anne C. , Stinchcombe, Tom, Gray, Jhanelle E. , Morgensztern, Daniel , Kozono, David , Osarogiagbon, Raymond U. , Stinchcombe, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.tps8113 Get It

TPS8113 Background: There are currently three approved approaches for patients with resectable NSCLC including neoadjuvant chemoimmunotherapy, adjuvant chemoimmunotherapy and perioperative treatment with neoadjuvant chemoimmunotherapy followed by adjuvant immunotherapy. All regimens were approved after showing event-free survival (EFS) or disease-free survival (DFS) benefit with the addition of immunotherapy to chemotherapy compared to chemotherapy alone. Each approach has its benefits and risks. Starting immunotherapy prior to surgery may improve treatment compliance and efficacy of immunotherapy. Nevertheless, neoadjuvant chemoimmunotherapy may result in missing an opportunity for curative surgery and increase the complexity of tumor resection. PROSPECT-LUNG (NCT06632327) is a randomized study evaluating whether starting chemoimmunotherapy before or after surgery leads to better outcomes. Methods: This is a randomized phase 3 trial in which patients will be randomized 1:1 to surgery followed by chemoimmunotherapy (adjuvant arm) or neoadjuvant chemoimmunotherapy followed by surgery and adjuvant therapy (perioperative arm). Patients with histologic or cytologic confirmation of surgically resectable stage IIA-IIIB NSCLC (per AJCC 9th edition) or stage IIA to IIIB per AJCC 8 th edition up to single ipsilateral mediastinal station (N2a), ECOG PS ≤ 2 (or Karnofsky ≥ 60%), no prior treatment for NSCLC and no previous malignancy within 3 years are eligible. The dual primary endpoints are real-world event free survival (rwEFS) defined as date from randomization to date of the first of the following events: failure to undergo resection for any reason, progression prior to surgery that precludes resection, recurrence or progression at any time after surgery or death from any cause, and overall survival (OS) defined as time from randomization to death from any cause. The target accrual is 1,100 patients assuming one-sided type I error of 0.03 for OS endpoint and 0.02 for rwEFS endpoint. This sample size will enable the detection of a 3-year rwEFS improvement from 55% in the adjuvant therapy arm to 64% in the perioperative arm with an 84% power. This sample size would detect an HR of 0.73 (improvement in median OS from 8.1 to 11 years in favor of the perioperative arm, 5-year OS from 65% in the adjuvant arm to 73% in the perioperative arm, assuming exponential survival) with 83.6% power. The study has a pragmatic design with minimal data collection, reporting of adverse events that lead to discontinuation of therapy, hospitalization or death only. It allows providers to choose therapy per standard of care (FDA approved or on NCCN), includes patients with ECOG performance status 2, permits use of local laboratory testing and imaging studies and determination of recurrence/progression will be done by local treating physicians with no use of RECIST. Clinical trial information: NCT06632327 .
Magnetic resonance imaging–based deep learning for predicting EGFR mutations in metastatic non-small cell lung cancer: A systematic review and meta-analysis.
Alrabadi, Bassel , Refai, Yamen , Marzouk, Hamza Anas , Abu-Irsheid, Loay , Marouf, Mahmoud, Marsool, Mohammed Dheyaa Marsool , Odat, Ramez M.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e14008 Get It

e14008 Background: Lung cancer is the most common cancer to metastasize to the brain. Identifying the EGFR mutation is critical for determining treatment strategies and prognosis. However, 17.26% of patients show EGFR mutation discordance between the primary tumor and CNS metastasis. On the other hand, it is not always feasible to obtain brain samples. Many studies have developed deep learning (DL) models to predict the existence of EGFR mutations using radiomics. In this paper, we aim to measure the accuracy of diagnostic tests in those studies. Methods: PubMed, Scopus, Cochrane Library and Web of Science databases were searched from inception to January 2025, to identify studies measuring the ability of DL models in differentiating between the types of EGFR mutation in patients with lung cancer brain metastases. The quality assessment of the included studies was performed using QUIPS tool. The diagnostic accuracy meta-analysis was conducted using Meta-DiSc software. Results: Nine studies were included in our systematic review and meta-analysis, encompassing 260 patients with EGFR mutant type and 264 patients with EGFR wild type. Our analysis revealed that DL approaches exhibit a high ability to differentiate between EGFR mutation types, with a sensitivity of 0.82 (95% CI: 0.73–0.88) and a specificity of 0.88 (95% CI: 0.78–0.94). Additionally, the positive likelihood ratio and negative likelihood ratio were 6.87 (95% CI: 3.5–13.3) and 0.20 (95% CI: 0.13–0.31), respectively. The diagnostic odds ratio was 33.4 (95% CI: 13.5–82.5), which is indicative of excellent diagnostic accuracy. Conclusions: DL models demonstrate exceptional diagnostic accuracy in detecting EGFR mutations in brain metastases from lung cancer. These findings highlight the potential of AI-driven approaches to enhance personalized treatment strategies and improve outcomes for patients with EGFR-mutant NSCLC brain metastases.
Incidence and treatment outcomes of small cell carcinoma of the small intestine, colon, and rectum.
Sun, Nian X. , Jin, Zhaohui , Sun, Nora

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e15682 Get It

e15682 Background: Small cell carcinoma (SCC) of gastrointestinal tract is a highly aggressive rare malignancy with an estimated prevalence of 0.1% to 1% of all GI neoplasms. Treatment and survival outcomes data are very limited. Here we present an analysis of outcomes of patients with intestinal SCC using data from the Survival, Epidemiology, and End Result (SEER) database. Methods: SEER (2000-2020) was used to identify patients with SCC involving of the small intestine, colon and rectum. Variables included age, race, site, stage, chemotherapy (chemo), radiation therapy (RT) and surgery. Cox regression was used to model survival outcomes based on site, stage, and treatment received in the overall group and stage subgroups. Results: 1,169 patients with SCC of the small intestine, colon, and rectum were identified. Median age was 65 (24-90). 631 (54%) were male; majority of patients were white (989; 85%), followed by black (128; 11%) and other races (50; 4.3%). Colon (569; 49%) and rectum (514; 44%) were the predominant sites while small intestine only comprised 7.4% of the patients. Distant, regional and local diseases were reported in 55%, 17% and 7.5% of the patients. Median overall survival (mOS) of the entire group was 8 months (m). Primary tumor sites of small intestine and rectum were significantly associated with lower mortality rate in comparison to colon (11 m and 9 m vs 5 m, p < 0.001 for both). Patients with localized disease had the lowest mortality rate when compared with those with regional or distant metastatic diseases (38 m vs. 16 m and 5 m, p < 0.001 for both). Receiving surgery (HR: 0.458, p < 0.001), chemo (HR: 0.473, p < 0.001), and RT (HR: 0.733, p = 0.003) were all significantly associated with lower mortality rate (Table). These differences remained significant in each stage-based subgroup except for chemotherapy in localized disease subgroup, which encompassed only 87 patients. Conclusions: Intestinal SCC has poor prognosis, with SCC of the colon being most prevalent and with the highest mortality. Majority of patients presented with distant metastatic disease which led to high mortality. Multimodality treatment may improve survival for these patients. Number of cases (%) HR (CI) p-value mOS (months) vs reference Site (ref: colon) Rectum 514 (44%) 0.750 (0.648-0.867) <0.001 9 (ref: 5) Small intestine 86 (7.4%) 0.574 (0.44-0.749) <0.001 11 (ref: 5) Stage (ref: localized) Regional 201 (17%) 2.087 (1.507-2.891) <0.001 16 (ref: 38) Distant 639 (55%) 4.222 (3.110-5.733) <0.001 5 (ref: 38) Unknown/unstaged 242 (21%) 1.639 (1.160-2.315) 0.005 8 (ref: 38) Chemo (ref: none/unknown) Yes 590 (50%) 0.473 (0.404-0.553) <0.001 10 (ref:3) RT (ref: none/unknown) Yes 175 (15%) 0.733 (0.598-0.897) 0.003 12 (ref: 7) Surgery (ref: no surgery) Yes 363 (31%) 0.458 (0.385-0.546) <0.001 12 (ref: 6) Unknown 138 (12%) 0.717 (0.549-0.936) 0.01 7.5 (ref: 6)
Real world outcomes of patients treated with tarlatamab in extensive stage small cell lung cancer.
Karam, Dhauna , Potter, Ashley , Al‐Ajmi, Abdullah, Mina, Syeda A. , Taylor, Skyler, Parikh, Kaushal , Shanshal, Mohamed , Molina, Julian R. , Luce, A., Schwecke, Anna J., Ernani, Vinicius , Lin, Yi , Leventakos, Konstantinos , Taylor, Skyler, Hazim, Antonious , Dimou, Anastasios , Mansfield, Aaron S. , Smith, Katherine E. , Schwecke, Anna, Manochakian, Rami

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e20120 Get It

e20120 Background: In May 2024, the FDA approved tarlatamab, a Delta-like ligand (DLL3)/CD3-targeted bispecific T-cell engager, for patients with extensive-stage small cell lung cancer (SCLC) with disease progression following platinum-based chemotherapy and at least one other prior line of therapy. We aim to evaluate the real-world outcomes of agent. Methods: We conducted a retrospective multi-site single center analysis of adult patients who received tarlatamab at Mayo clinic sites including Arizona, Florida, Iowa, Minnesota, and Wisconsin. Data analysis was performed with Blue Sky statistics version 10.4. Results: Twenty patients with a median age 67 years (range 43-76) were included. Patients were predominantly women (55%) and all had a history of tobacco use. Metastatic disease commonly involved liver (55%) and CNS (60%). Majority (90%) had received prior PDL-1 therapy. 25% (5/20) of patients received prior gamma knife and in addition 10% (2/20) received whole brain radiation treatment in our cohort. Median time from CNS radiation and tarlatamab initiation was 4 months (range 3-28). Other characteristics, outcomes, and toxicity are presented in Table 1. Cytokine release syndrome (CRS) Grade (G) 1 was observed in 45% patients. G 2, 3 and 4 CRS were observed in 5% patients respectively. G 1 CRS was managed with acetaminophen initially followed dexamethasone 10mg or methylprednisone 1g if no improvement in 24 hours. Tocilizumab was used 20% patients for G 1,2,3 and 4 CRS depending on clinical course. Immune effector cell-associated neurotoxicity (ICANS) G 1 occurred in 10% patients, followed by G 2 in 15% and G 3 in 5% patients. ICANS was managed in a multidisciplinary fashion. All patients had resolution of CRS and ICANS. Conclusions: In this study investigating the real-world outcomes and toxicity of tarlatamab, a higher incidence of ICANS was observed than that reported in the DeLLphi-301 trial. The association between presence of CNS metastatic disease, prior CNS radiation and incidence of ICANS needs to be explored further. Mayo Clinic report of tarlatamab real world outcomes and toxicity. Patient Characteristics, Tarlatamab Outcomes and Toxicity Mayo Clinic Report DeLLphi-301 trial- Part 1 & 2 DeLLphi-301 trial- Part 3 ECOG no. (%) 2-4 4 (20) 0 (0) 0 (0) Metastatic Disease no.(%) 19 (95) 98 (98) 32 (94) Median no. of previous lines of therapy (range) 3 (2-4) 2 (1-6) 2 (2-6) Objective Response (%) 30% 40% CRS no (%) 12 (60) 49 (49) 19 (56) ICANS no (%) 6 (30) 7 (7) 4 (12) Neutropenia Grade 3 no (%) 2 (10) 6 (6) 2 (6) Fatal CRS, ICANS or Neutropenia 0 (0) 0 (0) 0 (0)
Small nucleolar RNAs (snoRNAs) expression and effects on patient (pt) outcomes in metastatic colorectal cancer (mCRC): Data from CALGB (Alliance)/SWOG 80405.
Millstein, Joshua , Bartolini, Michela, Ashouri, Karam , Algaze, Sandra, Torres‐Gonzalez, Lesly , Shah, Unnati Hermant, Zhang, Wu, Innocenti, Federico , Lenz, Heinz‐Josef , Battaglin, Francesca , Soni, Shivani , Algaze, Sandra , Mittal, Pooja , Jayachandran, Priya , Shah, Unnati Hermant, Ou, Fang‐Shu , Venook, Alan P.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 3145-3145

10.1200/jco.2025.43.16_suppl.3145 Get It

3145 Background: SnoRNAs are non-coding RNAs that primarily guide the chemical modification of ribosomal RNA. Emerging evidence suggests snoRNAs play critical roles in cancer, including CRC, by regulating cell proliferation, apoptosis and tumor progression. Aberrant snoRNA expression has been linked to CRC development and poor prognosis, offering potential as diagnostic biomarkers and therapeutic targets. We investigated whether the tumor expression levels of 3 types of snoRNAs (SCARNA, SNORA, SNORD) affect treatment response in pts enrolled in CALGB/SWOG 80405 (NCT00265850). Methods: 433 mCRC pts treated with bevacizumab (bev, n = 226) or cetuximab (cet, n = 207) in combination with first-line chemotherapy were analyzed. RNA was isolated from FFPE tumor samples and sequenced on the HiSeq 2500 (Illumina). 422 snoRNAs were evaluated (23 SCARNA, 140 SNORA, 259 SNORD). Overall survival (OS) and progression-free survival (PFS) were compared across tertiles of gene expression (high [H], medium [M], low [L]) by multivariable Cox proportional hazards models adjusted for age, sex, ECOG performance status, tumor side, number of metastatic sites, KRAS , CMS subtypes, and treatment. Interaction tests for the predictive effect (bev vs cet) were performed. P -values were corrected for multiple testing using the Benjamini-Hochberg approach ( q < 0.05). Results: Only SCARNA21 achieved statistical significance for OS after false discovery rate (FDR) adjustment. Tumors with H levels of SCARNA21 had shorter survival compared to tumors with M or L expression (median OS 24.4 vs 32.4 vs 33.9 months, respectively; P = 0.0015, q = 0.033), independent of treatment. No snoRNAs achieved FDR significance for PFS. However, several snoRNAs showed significant treatment interactions with biologic agents. SCARNA6-H and SCARNA5-H tumors had longer PFS and OS when treated with cet, but shorter PFS and OS when treated with bev, compared to the M and L expression groups (PFS interaction q = 0.0067 and 0.045, respectively; OS interaction q = 0.022 and 0.034, respectively). SCARNA7 also showed significant treatment interaction for OS, favoring cet in the H expression group ( q = 0.018); the opposite was observed for SNORA63B, SNORA63D, SNORA35B, and SNORA36C ( q = 0.027, 0.027, 0.027 and 0.047, respectively). No significant results were observed for any of the tested SNORDs. Conclusions: SnoRNAs dysregulation affects key pathways such as cell cycle control and immune evasion, making them promising players in CRC biology. Our study highlights the prognostic and predictive potential of specific snoRNAs in mCRC. Notably, high SCARNA21 expression was linked to shorter OS, while SCARNA5 and 6 showed predictive value for treatment response, indicating their potential for guiding treatment decisions. Further validation is needed to confirm these findings, and mechanistic studies are warranted.
Paraneoplastic syndromes in non-small cell lung carcinoma: A systematic review of case reports and case series.
Gore, Shivanjali , Rosamystica, Meisya , Sarangi, Swapna , Arshad, Zara , Huynh, Chanh Trung, Nawaz, Faisal, Bansal, Vikas , Kashyap, Rahul

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e20041 Get It

e20041 Background: Paraneoplastic syndromes (PNS) are caused by underlying malignancy but not due to metastasis, or treatment related side effects. Studies are lacking which target PNS seen in non small cell lung cancer (NSCLC) Methods: Systematic search of PubMed & Scopus was conducted to include all case reports & case series of adult NSCLC patients with PNS, published globally from inception upto July 7, 2024. Patient demographics, geographical distribution, NSCLC histology, clinical manifestations, diagnosis, treatment was extracted. Quality was assessed by JBI's critical appraisal checklist. Results: 138 publications (136 case reports, 2 case series) describing 142 patients published in 30 countries were included. Majority patients were male (69.7%) with mean age 57 years. Top publishing countries were USA (28.2%), Japan (13%), China (6.5%), Germany (5%), with publications (n=16) peak seen in 2020. Histological type of NSCLC with PNS was adenocarcinoma (39.8%), SCC (26.8%), unspecified histology (13%) & large cell (8.6%). Most common PNS seen in NSCLC were hypertrophic osteoarthropathy (7.2%), bilateral diffuse uveal melanocytic proliferation (5.7%), leukemoid reaction (4.3%) & limbic encephalitis (4.3%). Conclusions: Study provides bird’s eye view of all PNS found in NSCLC, aiding in timely diagnosis & treatment of NSCLC. Organ system PNS Cases Neurology Limbic encephalitisOpsoclonus myoclonus syndromeGBSSensorimotor peripheral neuropathyCerebellar degenerationEncephalomyelitisPerson in barrel syndromeMyoclonusPandysautonomiaNeuromyelitis opticaOpsoclonusAntiHu Ab neuropathyMononeuritis multiplexMorvan syndrome 63221111111111 Cardiology & haematology Leukemoid reactionLeukocytoclastic vasculitisHSPDICITPMyelofibrosisAcral vascular cyanosisHyper eosinophiliaHeart blockTrousseau syndromeHaemophilia ASVC syndromeChurg Strauss syndrome 6332211111111 Endocrinology SIADHCushing syndromeHypercalcemia of malignancyGynaecomastiaβ HCG secretionErectile dysfunction 433221 Rheumatology Hypertrophic osteoarthropathyPolyarthritisPolymyositisDermatomyositisMyasthenia gravisLambert Eaton syndromePolymyalgia rheumaticaSclerodermaRaynaud phenomenonAnti synthetase syndrome 10433311111 Dermatology Bazex syndromeBullous pemphigoidErythema gyratumLeser Trélat Tripe palmsErythrodermaIchthyosisAcanthosis nigricansRhinophymaGranuloma annularePityriasis rubria pilarisEczemaErythema induratumHyperhidrosis 42212111111111 Ophthalmology Bilateral diffuse uveal melanocytic proliferationCancer associated retinopathyCicatrizing conjunctivitisRetinal detachmentOrbital inflammationOcular flutterProptosis 8311111 Nephrology Nephrotic syndrome 3 Gastroenterology Pseudo achalasiaVerner Morrison syndromeGranulomatous visceral neuronopathy 111 Musculoskeletal Necrotizing myopathy 2
Small intestinal microbial fiber metabolism dysfunction in celiac disease
Verdú, Elena F. , Wulczynski, Mark, Blom, Jedid-Jah , Rueda, Gaston , El-Chaar, Nader N., Superdock, Dorothy K. , Jiang, Sharon, David, Lawrence A. , Armstrong, David , Berčík, Přemysl , El-Chaar, N , Superdock, D K , David, L A , Surette, M G , Bercik, Premysl , Caminero, A , Verdu, Elena F , Constante, Marco , Galipeau, Heather J. , Rueda, Gaston H., Murray, Joseph A. , Armstrong, David , Pinto-Sánchez, María Inés , Caminero, Alberto

Mayo Clinic

No container title available | May 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6572358/v1 | PMID 40470242 Get It

Abstract Celiac disease (CeD) is an immune-mediated condition driven by dietary gluten resulting in small intestinal mucosal inflammation and injury, along with myriads of symptoms. The only treatment is a lifelong gluten-free diet (GFD) and although most patients improve, the restriction can lead to nutrient deficiencies including fiber. While duodenal microbiota is altered in CeD, its fiber metabolic capacity is unknown. Here we show that both active and GFD-treated CeD patients had impaired microbial fiber metabolism in the small intestine which associates with depletion of the carbolytic taxa Prevotella spp. Colonization of germ-free mice with Prevotella spp increased small intestinal short chain fatty acids (SCFA). In gluten-sensitized mice expressing the celiac risk gene, HLA-DQ8, an inulin-supplemented diet facilitated microbial carbolytic function, SCFAs production and accelerated mucosal healing in the small intestine during GFD. The results support clinical investigations of dietary fiber supplementation and microbial carbolytic function to enhance responses to GFD in CeD.
Epigenomic and Transcriptomic Regulation of the MUC5B/MUC5AC Locus in Bronchial Airway Epithelium and Association With Early Small Airways Disease in Spiromics
Ortega, Victor E. , Chen, Xinyi , Shrivastav, A.K. , Zein, Joe , Howard, Timothy D. , Hawkins, Gregory A., Bowler, R.P., Comellas, Alejandro P. , Cooper, C.B. , Galbán, Craig J. , Hansel, Nadia N. , Hastie, Annette T. , Kanner, Richard E. , Martinez, F.J., Paine, Robert , Hoffman, E.A., Meyers, Deborah A. , Woodruff, P., Curtis, J.L., Bleecker, E.R., Christenson, S., C, NHLBI Subpopulations and Intermediate Outcomes Measures in, Christenson, Stephanie A. , Comellas, Alejandro P , Christenson, Stephanie A , Shrivastav, A.K., Barjaktarević, Igor , Barr, R. Graham , Couper, David , Han, MeiLan King , Kaner, Robert J. , Martinez, F.J., O’Neal, Wanda K. , Hoffman, E.A., Curtis, J.L., Huang, Yvonne J

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5245-A5245

10.1164/ajrccm.2025.211.abstracts.a5245 Get It

Abstract Rationale: MUC5B and MUC5AC are neighboring genes on chromosome 11p15 that encode the two predominant mucins secreted in the respiratory airways. Increased airway mucin concentrations and an imbalance between these two mucins drive COPD symptoms and the development of airflow obstruction or COPD, but the epigenomic regulation of this loci has not been characterized in the airways. Methods: We isolated DNA from bronchial airway brushings of 72 participants with &gt;20 pack-years smoking history from the Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS). 36 participants had GOLD-based moderate-to-severe COPD (FEV1/FVC&lt;0.70, FEV1&lt;80%) and 36 were without or with mild COPD. We used the Illumina Infinium Methylation EPIC BeadChip Array to assess proportion of DNA methylation (β) spanning 689,937 CpG sites. We evaluated proportional DNA methylation (β) at 96 CpG loci within a 103kB region using matrixQTL for cis-expression quantitative trait methylation (eQTM: 10kB flanks relative to MUC5AC/MUC5B) integrating bulk RNA-seq data and mQTL models integrating gene sequencing data to identify DNA variation associated with proportion eQTM methylation. Models included age, sex, BMI, clinical site, current smoking vs past smoking, total pack-years, three ancestral components of ancestry, chipset, and position. Results: We identified a top eQTM, cg00524486, marginally associated with MUC5B expression (coefficient estimate=8.75, punadjusted=0.0014, pFDR=0.065, Figure 1B). This eQTM was associated with CT scan parametric response mapping-based functional small airways disease (PRM-fSAD, beta coefficient[β]=3.64, p=0.011). We tested for DNA variation associated with methylation of this top eQTM which identified two methylation quantitative trait loci (mQTL: rs885454 [β=0.044, minor allele frequency[MAF]=0.09, pFDR=0.01], rs868902 [β=0.020, MAF=0.43, pFDR=0.08, Figure 1A) associated with cg00524486 methylation, of which the more frequent mQTL, rs868902, was marginally associated with PRM-fSAD (p=0.07) in the larger SPIROMICS cohort with MUC5B DNA sequencing data. Conclusions: This preliminary multi-omic study of the lower airway epithelium demonstrates that the expression of MUC5B is epigenetically regulated by neighboring CpG probe methylation (eQTM) represented by DNA variation (mQTL). These studies require further confirmation in a larger dataset of airway samples and support a role for epigenetic variation as a biologic contributor and biomarker of early COPD pathogenesis.
3D‐Printed Microfluidic Platform for Creating Porous Nanofibrous Microspheres to Regulate Cell Response and Enhance Tissue Regeneration
Lee, Dong-Hee , Tran, Huy Quang , Sharma, Navatha Shree , Yan, Zishuo , Killeen, Amy C., Reinhardt, Richard A., Zhu, Wuqiang , Xie, Jingwei , Zhu, Wuqiang , Andrabi, Syed Muntazir , Xie, Jingwei

Mayo Clinic

Small | May 2, 2025 | Volume: 21 | Issue: 41 | Pages: No page available

10.1002/smll.202502033 | PMID 40318101 Get It

Abstract Porous nanofibrous microspheres (PNMs) present a versatile and minimally invasive strategy for tissue regeneration, combining biomimetic morphology, tunable structure, and injectability. While self‐assembly and co‐axial electrospray are explored for PNM fabrication, these methods are limited in compositional versatility and production scalability. Here, a 3D‐printed microfluidic platform is presented that enables large‐scale fabrication of PNMs with precise control over size, pore architecture, and morphology. PNMs can be functionalized with bioactive molecules through UV crosslinking, enhancing their regenerative potential by promoting osteogenesis in human bone marrow stromal cells (hBMSCs), angiogenesis in human umbilical vein endothelial cells (HUVECs), and exerting anti‐inflammatory effects on macrophages. Subcutaneous implantation in rats demonstrates that PNMs support cell infiltration, minimize fibrosis, and facilitate tissue integration, achieving complete cell penetration and tissue incorporation within 14 days. These findings establish PNMs as versatile, scalable, and customizable platforms, ideal for applications as injectable drugs or cell carriers, as well as powders, offering promising solutions for wound healing and tissue regeneration.
Perioperative Therapy in Oncogene-Driven Non–Small Cell Lung Cancer: Current Strategies and Unanswered Questions
Voruganti, Teja , Marar, Rosalyn, Bleiberg, Benjamin Aaron , Garbo, Edoardo , Parikh, Kaushal , Aggarwal, Charu , Aggarwal, Charu , Garbo, Edoardo , Ricciuti, Biagio

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 1, 2025 | Volume: 45 | Issue: 3 | Pages: No page available

10.1200/edbk-25-472804 | PMID 40311093 Get It

Perioperative therapy has become a critical component in the management of resectable non–small cell lung cancer (NSCLC), particularly in the era of precision medicine. Although molecular testing is standard in metastatic NSCLC, its incorporation into early-stage disease remains essential for guiding treatment decisions. Reflex molecular testing pathways are necessary to optimize tissue utilization and ensure timely results. However, liquid biopsies, although valuable in advanced disease, have limited sensitivity in early-stage NSCLC, reinforcing the need for tissue-based next-generation sequencing. Targeted therapies have revolutionized treatment for oncogene-driven NSCLC, with adjuvant osimertinib now standard for EGFR-mutant disease and ongoing investigations into ALK tyrosine kinase inhibitors (TKIs). However, unanswered questions remain regarding the inclusion of perioperative TKI therapy, the role of molecular residual disease assessment, and whether specific TKIs offer greater benefit for high-risk subgroups. The role of immunotherapy (IO) in oncogene-driven NSCLC remains controversial. Although perioperative chemo-IO has demonstrated survival benefits in unselected NSCLC, its efficacy in EGFR, ALK, and other actionable alterations is unclear. Tumors harboring KRAS and BRAF mutations may respond better because of a more immune-inflamed microenvironment, and remains an active area of investigation. As the landscape of perioperative therapy continues to evolve, ongoing trials will help define the optimal integration of targeted therapies and IO in oncogene-driven NSCLC. Addressing these unanswered questions will be crucial in refining treatment strategies and improving patient outcomes.